Kythera earns $15.8m payment from Bayer under ATX-101 licensing deal
The agreement was signed in August 2010 for the development and commercialization of injectable drug candidate, ATX-101, outside the US and Canada. Kythera also received €14.1m ($17.5m) to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.